UBS AM’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $323M | Sell |
|
|||||
|
2025
Q2 | $313M | Buy |
|
|||||
|
2025
Q1 | $199M | Buy |
|
|||||
|
2024
Q4 | $167M | Buy |
|
|||||
|
2024
Q3 | $194M | Sell |
|
|||||
|
2024
Q2 | $203M | Buy |
|
|||||
|
2024
Q1 | $113M | Buy |
|
|||||
|
2023
Q4 | $142M | Sell |
|
|||||
|
2023
Q3 | $137M | Buy |
|
|||||
|
2023
Q2 | $135M | Hold |
|
|||||
|
2023
Q1 | $135M | Buy |
|
|||||
|
2022
Q4 | $156M | Buy |
|
|||||
|
2022
Q3 | $121M | Buy |
|
|||||
|
2022
Q2 | $86.5M | Sell |
|
|||||
|
2022
Q1 | $98.8M | Sell |
|
|||||
|
2021
Q4 | $109M | Sell |
|
|||||
|
2021
Q3 | $122M | Buy |
|
|||||
|
2021
Q2 | $106M | Sell |
|
|||||
|
2021
Q1 | $94M | Sell |
|
|||||
|
2020
Q4 | $91.7M | Sell |
|
|||||
|
2020
Q3 | $105M | Sell |
|
|||||
|
2020
Q2 | $124M | Buy |
|
|||||
|
2020
Q1 | $90.5M | Buy |
|
|||||
|
2019
Q4 | $94.9M | Buy |
|
|||||
|
2019
Q3 | $63.6M | Sell |
|
|||||
|
2019
Q2 | $70M | Sell |
|
|||||
|
2019
Q1 | $108M | Sell |
|
|||||
|
2018
Q4 | $103M | Buy |
|
|||||
|
2018
Q3 | $116M | Sell |
|
|||||
|
2018
Q2 | $134M | Buy |
|
|||||
|
2018
Q1 | $160M | Sell |
|
|||||
|
2017
Q4 | $177M | Buy |
|
|||||
|
2017
Q3 | $160M | Sell |
|
|||||
|
2017
Q2 | $116M | Sell |
|
|||||
|
2017
Q1 | $88.7M | Buy |
|
|||||
|
2016
Q4 | $62.4M | Buy |
|
|||||
|
2016
Q3 | $103M | Sell |
|
|||||
|
2016
Q2 | $92.3M | Buy |
|
|||||
|
2016
Q1 | $104M | Sell |
|
|||||
|
2015
Q4 | $181M | Buy |
|
|||||
|
2015
Q3 | $154M | Buy |
|
|||||
|
2015
Q2 | $218M | Buy |
|
|||||
|
2015
Q1 | $185M | Buy |
|
|||||
|
2014
Q4 | $155M | Sell |
|
|||||
|
2014
Q3 | $135M | Buy |
|
|||||
|
2014
Q2 | $108M | Buy |
|
|||||
|
2014
Q1 | $112M | Buy |
|
|||||
|
2013
Q4 | $102M | Buy |
|
|||||
|
2013
Q3 | $78.5M | Sell |
|
|||||
|
2013
Q2 | $41.7M | Buy |
|